AstraZeneca MDD 031
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-controlled, Phase IIB Efficacy and Safety Study of Adjunctive AZD6765 in Patients with Major Depressive Disorder (MDD) and a History of Inadequate Response to Antidepressants.
| Protocol | |
|---|
| Identifier | D6702C00031 |
|---|
| UID | b6a658c9-cd01-4b5d-9f96-1d09d797a0ee |
|---|
| Status | Done - Archived |
|---|
| Phase | 2B |
|---|
| Category | Major Depressive Disorder / Adult |
|---|
| Launch Year | 2012 |
|---|
| NCT Number | - |
|---|
| Created | 2012-05-14 14:48 |
|---|
| Last Updated | 2012-05-14 14:48 |
|---|
Description
Key Elements:
• Male and Female patients 18 to 70 years old inclusive.
• To evaluate the efficacy of AZD676165iv given intravenously in 50mg or 100mg/ infusion as adjunct to current antidepressant medication versus antidepressant medication + placebo in the treatment if patients with inadequate response to antidepressant treatment.
• Patients who have exhibited an inadequate response to 3 or more different antidepressant treatment by history. One of which may include the current antidepressant medication.
Comment
No comment.
